GBL

Gamma-butyrolactone (GBL) is a clear, colorless industrial solvent and chemical intermediate that functions as a prodrug of GHB (gamma-hydroxybutyrate) through rapid lactonase-mediated hydrolysis in the body. Upon ingestion, the lactone ring of GBL is opened by lactonase enzymes present in blood and liver tissue to yield GHB directly, producing effects pharmacologically identical to GHB — sedation, euphoria, anxiolysis, and dose-dependent amnesia — but with a significantly faster onset than either GHB or its other prodrug, 1,4-butanediol (1,4-BD). GBL is converted to GHB essentially instantaneously upon contact with physiological fluids, producing onset within 5–15 minutes by oral route.

GBL occupies a critical position in the harm reduction landscape of GABAergic depressants: it produces identically the same effects and risks as GHB while having a substantially faster and more predictable onset than 1,4-BD, but the speed of onset combined with the narrow therapeutic window of the GHB class creates an even more compressed window between a recreational dose and a potentially fatal one. The difference between a dose that produces pleasant effects and one that causes unconsciousness may be as small as 0.5 mL; this window narrows dramatically with any concurrent alcohol use and varies with gastric contents.

Community experience underscores GBL's severe dependence liability — likely even higher than 1,4-BD due to the more efficient conversion and faster onset — and the harrowing nature of GHB/GBL withdrawal, which can include psychosis, seizures, and profound autonomic instability refractory to benzodiazepine treatment. GBL has historically been used at LGBTQ+ party settings and chemsex contexts in Europe, where harm reduction outreach has developed specific evidence-based guidance for this population. The industrial solvent status of GBL complicates regulation, as it has numerous legitimate commercial applications.